Skip to Content

Posts tagged with "The Dark Side"

  • The Dark Side

    Thoughts on Reproducibility

    Not too long ago, I was talking to someone outside the field about the “reproducibility crisis”. They’d heard that there were many published papers whose results weren’t solid, and wanted to know if I’d encountered that. I had to tell them that yep, I sure had, and that just about anyone who’s worked in any… Read More
  • Alzheimer's Disease

    Neurotrope: A Shameful PR Stunt

    There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases, and a grievous lack of understanding of statistics. Via @AndyBiotech and @biotechtoreador on Twitter, I came across this release about an announcement from a small company called Neurot… Read More
  • Cardiovascular Disease

    A Clinical Trial Torpedoed By Fraud and Incompetence

    Via @AndyBiotech on Twitter, here’s a story on some very troubling developments in offshore clinical trials. That Cardiobrief article is referring to this letter in NEJM, and the subject is the NIH’s trial of spironolactone in heart failure patients. The TOPCAT trial enrolled 3445 participants  in 6 countries (1151 in the US, 326 i… Read More
  • Business and Markets

    Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track, because there’s a lot of odd behavior down in those companies (here’s another recent example with Cyclacel). Here’s a welcome update to the earlier stories, courtesy of t… Read More
  • The Dark Side

    The Predatory Beat Goes On

    I’m not the least bit surprised by this effort. The predatory junk journals will do what ever they can think of to bring in customers and cash, with no restrictions and no shame: . . .we created a profile of a fictitious scientist named Anna O. Szust and applied on her behalf to the editorial… Read More
  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
  • Drug Prices

    The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, right? That’s apparently what Marathon Pharmaceuticals believes. They just got approval for deflazacort, a steroid, as a treatment for Duchenne Muscular Dystrophy. Duchenne is… Read More
  • Business and Markets

    Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit of an odd feeling at first – I can remember getting together with some friends from school not long after I’d taken my first pharma job (they had also… Read More
  • The Dark Side

    The Predatory Publishers List Goes Dark

    I’ve been meaning to write about the sudden demise of Beall’s List of Predatory Publishers. I’ve referred to it several times over the years in posts about the lower (much lower) end of the scientific publishing world, and used it many times as a resource. To recap, while there are many reputable open-access publishers in… Read More
  • Cancer

    Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you hear that your body has to be alkaline, and that cancer and other diseases are associated with acidity. To save time, I will stipulate that this is bullshit. Read More
...234...